<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00433654</url>
  </required_header>
  <id_info>
    <org_study_id>212</org_study_id>
    <nct_id>NCT00433654</nct_id>
  </id_info>
  <brief_title>EMRI SureScan™ Clinical Study</brief_title>
  <official_title>EnRhythm MRI™ SureScan™ Pacing System Clinical Investigation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiac Rhythm and Heart Failure</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiac Rhythm and Heart Failure</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to confirm safety and efficacy in the clinical magnetic
      resonance imaging (MRI) environment of the investigational EnRhythm MRI™ SureScan™ Pacing
      System (used in support of Revo MRI™ SureScan Pacing System launch).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, multi-center global study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Magnetic Resonance Imaging (MRI)-Related Complications</measure>
    <time_frame>MRI scan to one-month post-MRI scan</time_frame>
    <description>Subjects with a complication related to the MRI scan. All adverse events in the time frame were recorded at the subject's center and assessed by a centralized Adverse Event Advisory Committee. The committee determined whether each adverse event was a complication (requiring invasive intervention), and whether the event was related to the MRI scan.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Atrial Pacing Capture Threshold Success</measure>
    <time_frame>9-12 week visit to 4-month visit</time_frame>
    <description>Subjects' atrial pacing capture threshold (the energy sent from the pacemaker needed to make the heart's atrium beat) was measured at the 9-12 week visit (before the MRI scan was performed for those in the MRI group) and at the 4-month visit (one month post-MRI). Subjects were considered successful if their pacing capture threshold did not increase by 1.0 volt (V) or more.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ventricular Pacing Capture Threshold Success</measure>
    <time_frame>9-12 week visit to 4-month visit</time_frame>
    <description>Subjects' ventricular pacing capture threshold (the energy sent from the pacemaker needed to make the heart's ventricle beat) was measured at the 9-12 week visit (before the MRI scan was performed for those in the MRI group) and at the 4-month visit (one month post-MRI). Subjects were considered successful if their pacing capture threshold did not increase by 1.0 volt (V) or more.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Atrial Sensed Amplitude Success</measure>
    <time_frame>9-12 week visit to 4-month visit</time_frame>
    <description>Subjects' atrial sensed amplitude (the minimum energy produced by the heart's atrium that the pacemaker can sense) was measured at the 9-12 week visit (before the MRI scan was performed for those in the MRI group) and at the 4-month visit (one month post-MRI). Subjects were considered successful if their sensed amplitude did not decrease by more than 50% and remained above 1.5 millivolts (mV).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ventricular Sensed Amplitude Success</measure>
    <time_frame>9-12 week visit to 4-month visit</time_frame>
    <description>Subjects' ventricular sensed amplitude (the minimum energy produced by the heart's ventricle that the pacemaker can sense) was measured at the 9-12 week visit (before the MRI scan was performed for those in the MRI group) and at the 4-month visit (one month post-MRI). Subjects were considered successful if their sensed amplitude did not decrease by more than 50% and remained above 5.0 millivolts (mV).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjects With System-related Complications</measure>
    <time_frame>Implant to 4 Months</time_frame>
    <description>Subjects with a complication related to the implanted system, which consisted of the pacemaker, leads to the right chambers of the heart (atrium and ventricle), pacemaker software, and programmer. All adverse events in the time frame were recorded at the subject's center and assessed by a centralized Adverse Event Advisory Committee. The committee determined whether each adverse event was a complication (requiring invasive intervention), and whether the event was related to the system.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>System Related Adverse Device Effects Due to Labeling Instructions</measure>
    <time_frame>Implant through 18 months post-implant</time_frame>
    <description>Number of participants with adverse device effects (ADEs) that resulted from insufficiencies or inadequacies in the instructions for use or deployment of the device, or from user error. ADE's were investigator-reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Arrhythmias</measure>
    <time_frame>During the MRI scan</time_frame>
    <description>Number of participants with sustained ventricular arrhythmias or asystole episodes that occurred during the MRI scan that were considered attributable to the MRI scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial Lead Impedance Change</measure>
    <time_frame>9-12 week visit and 4-month visit</time_frame>
    <description>Subjects' atrial lead impedance (a measure of electrical resistance) was measured at the 9-12 week visit (before the MRI scan was performed for those in the MRI group) and at the 4-month visit (one month post-MRI). Both measurements were conducted by the pacemaker. The difference between the two is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventricular Lead Impedance Change</measure>
    <time_frame>9-12 week visit and 4-month visit</time_frame>
    <description>Subjects' ventricular lead impedance (a measure of electrical resistance) was measured at the 9-12 week visit (before the MRI scan was performed for those in the MRI group) and at the 4-month visit (one month post-MRI). Both measurements were conducted by the pacemaker. The difference between the two is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial Lead Handling Rating</measure>
    <time_frame>During implant</time_frame>
    <description>Physicians' rated atrial lead handling during the implant on a scale of -3 to +3 where: -3 = well below expectations; -2 = moderately below expectations; -1 = slightly below expectations; 0 = met expectations; +1 = slightly above expectations; +2 = moderately above expectations; and +3 = well above expectations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventricular Lead Handling Rating</measure>
    <time_frame>During implant</time_frame>
    <description>Physicians' rated ventricular lead handling during the implant on a scale of -3 to +3 where: -3 = well below expectations; -2 = moderately below expectations; -1 = slightly below expectations; 0 = met expectations; +1 = slightly above expectations; +2 = moderately above expectations; and +3 = well above expectations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial Pacing Capture Threshold</measure>
    <time_frame>3 or 4 months post-implant</time_frame>
    <description>Average atrial pacing capture threshold. Pacing capture threshold is the energy needed to pace the heart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventricular Pacing Capture Threshold</measure>
    <time_frame>3 or 4 months post-implant</time_frame>
    <description>Average ventricular pacing capture threshold. Pacing capture threshold is the energy needed to pace the heart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial Sensed Amplitude</measure>
    <time_frame>3 or 4 months post-implant</time_frame>
    <description>Average atrial sensed amplitude.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventricular Sensed Amplitude</measure>
    <time_frame>3 or 4 months post-implant</time_frame>
    <description>Average ventricular sensed amplitude.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">484</enrollment>
  <condition>Bradycardia</condition>
  <condition>Slow Heart Beat</condition>
  <arm_group>
    <arm_group_label>MRI group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The MRI group underwent a one-hour MRI scan at the 9-12 weeks post-implant follow-up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The control group waited for one hour (no MRI) at the 9-12 weeks post-implant follow-up.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantable Pulse Generator (IPG) and Pacing Leads (wires)</intervention_name>
    <description>Pacer and leads</description>
    <arm_group_label>MRI group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Magnetic Resonance Imaging (MRI) scan</intervention_name>
    <description>One hour MRI scan on the head and lower back.</description>
    <arm_group_label>MRI group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has, or is at risk of having, a heart beat that is too slow and his/her doctor
             has determined he/she needs a pacemaker.

          -  Subject available for follow-up at study center for length of study.

          -  Subject able and willing to undergo elective MRI scanning without sedation.

        Exclusion Criteria:

          -  Subject has, or is at risk of having, a heart beat that is too fast and his/her doctor
             has determined he/she needs an implantable cardioverter defibrillator (ICD).

          -  Subject needs or will need another MRI-scan, other than those required by the study,
             during the required study follow-up period.

          -  Pregnant women, or women of child bearing potential who are not on a reliable form of
             birth control.

          -  Subject with exclusion criteria required by local law.

          -  Subject who intends to participate in another clinical study during this clinical
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>EMRI SureScan Clinical Study Team</last_name>
    <role>Study Chair</role>
    <affiliation>Medtronic</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salinas</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Peachtree City</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mons</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bad Nauheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dortmund</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gottingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Asti</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pietra Ligure</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Viterbo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Denmark</country>
  </removed_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2007</study_first_submitted>
  <study_first_submitted_qc>February 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2007</study_first_posted>
  <results_first_submitted>January 11, 2011</results_first_submitted>
  <results_first_submitted_qc>July 18, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 11, 2011</results_first_posted>
  <disposition_first_submitted>September 29, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>September 29, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 1, 2009</disposition_first_posted>
  <last_update_submitted>October 17, 2011</last_update_submitted>
  <last_update_submitted_qc>October 17, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2011</last_update_posted>
  <responsible_party>
    <name_title>EMRI Clinical Research Specialist</name_title>
    <organization>Medtronic, Inc.</organization>
  </responsible_party>
  <keyword>Bradycardia</keyword>
  <keyword>Slow heart beat</keyword>
  <keyword>Magnetic resonance imaging (MRI)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bradycardia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first implant occurred 5 February 2007. A total of 484 subjects were enrolled, including 113 enrollments at 13 centers in the US and 371 enrollments at 29 centers outside of the US.</recruitment_details>
      <pre_assignment_details>Implant procedure included EnRhythm MRI SureScan pacemaker and 2 CapsureFix MRI 5086MRI leads. Pacemaker function and adverse events were assessed. 17 subjects did not have an implant attempt. 3 subjects received a subset of the 3 system components and were followed for safety. All other subjects were randomized after successful implant.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MRI Group</title>
          <description>The MRI group underwent a one-hour MRI scan at 9-12 weeks post-implant.</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>The control group waited for one hour (no MRI scan) at 9-12 weeks post-implant</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="258"/>
                <participants group_id="P2" count="206"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="243">Subjects completing the 4-month follow-up.</participants>
                <participants group_id="P2" count="201">Subjects completing the 4-month follow-up.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed visit</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject not yet due for visit</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MRI Group</title>
          <description>The MRI group underwent a one-hour MRI scan at 9-12 weeks post-implant.</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>The control group waited for one hour (did not have an MRI scan) at 9-12 weeks post-implant.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="258"/>
            <count group_id="B2" value="206"/>
            <count group_id="B3" value="464"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="183"/>
                    <measurement group_id="B2" value="139"/>
                    <measurement group_id="B3" value="322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.3" spread="12.9"/>
                    <measurement group_id="B2" value="68.0" spread="12.6"/>
                    <measurement group_id="B3" value="68.7" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="154"/>
                    <measurement group_id="B2" value="135"/>
                    <measurement group_id="B3" value="289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="157"/>
                    <measurement group_id="B2" value="141"/>
                    <measurement group_id="B3" value="298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Middle East</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Magnetic Resonance Imaging (MRI)-Related Complications</title>
        <description>Subjects with a complication related to the MRI scan. All adverse events in the time frame were recorded at the subject's center and assessed by a centralized Adverse Event Advisory Committee. The committee determined whether each adverse event was a complication (requiring invasive intervention), and whether the event was related to the MRI scan.</description>
        <time_frame>MRI scan to one-month post-MRI scan</time_frame>
        <population>Subjects who underwent an MRI scan following study protocol-specified instructions are included. Of the 243 subjects who completed a one-month post-MRI (4-month) visit, 32 did not complete the MRI scan according to the protocol instructions, and are not included.</population>
        <group_list>
          <group group_id="O1">
            <title>MRI Group</title>
            <description>The MRI group underwent a one-hour MRI scan at 9-12 weeks post-implant.</description>
          </group>
        </group_list>
        <measure>
          <title>Magnetic Resonance Imaging (MRI)-Related Complications</title>
          <description>Subjects with a complication related to the MRI scan. All adverse events in the time frame were recorded at the subject's center and assessed by a centralized Adverse Event Advisory Committee. The committee determined whether each adverse event was a complication (requiring invasive intervention), and whether the event was related to the MRI scan.</description>
          <population>Subjects who underwent an MRI scan following study protocol-specified instructions are included. Of the 243 subjects who completed a one-month post-MRI (4-month) visit, 32 did not complete the MRI scan according to the protocol instructions, and are not included.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: rate &gt; 10%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>exact test of binomial proportions</method>
            <param_type>Percentage</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>1.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Atrial Pacing Capture Threshold Success</title>
        <description>Subjects' atrial pacing capture threshold (the energy sent from the pacemaker needed to make the heart's atrium beat) was measured at the 9-12 week visit (before the MRI scan was performed for those in the MRI group) and at the 4-month visit (one month post-MRI). Subjects were considered successful if their pacing capture threshold did not increase by 1.0 volt (V) or more.</description>
        <time_frame>9-12 week visit to 4-month visit</time_frame>
        <population>Subjects were excluded from this analysis if: they did not have atrial pacing capture threshold measurements at 9-12 weeks or 4 months; or (for the MRI group) their MRI scan was not done according to protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>MRI Group</title>
            <description>The MRI group underwent a one-hour MRI scan at 9-12 weeks post-implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>The control group waited for one hour (no MRI) at the 9-12 week follow-up.</description>
          </group>
        </group_list>
        <measure>
          <title>Atrial Pacing Capture Threshold Success</title>
          <description>Subjects' atrial pacing capture threshold (the energy sent from the pacemaker needed to make the heart's atrium beat) was measured at the 9-12 week visit (before the MRI scan was performed for those in the MRI group) and at the 4-month visit (one month post-MRI). Subjects were considered successful if their pacing capture threshold did not increase by 1.0 volt (V) or more.</description>
          <population>Subjects were excluded from this analysis if: they did not have atrial pacing capture threshold measurements at 9-12 weeks or 4 months; or (for the MRI group) their MRI scan was not done according to protocol.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165"/>
                    <measurement group_id="O2" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: success rate MRI group &lt;= success rate control group - 10%</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin is 10%.</non_inferiority_desc>
            <param_type>Difference in percentages</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ventricular Pacing Capture Threshold Success</title>
        <description>Subjects' ventricular pacing capture threshold (the energy sent from the pacemaker needed to make the heart's ventricle beat) was measured at the 9-12 week visit (before the MRI scan was performed for those in the MRI group) and at the 4-month visit (one month post-MRI). Subjects were considered successful if their pacing capture threshold did not increase by 1.0 volt (V) or more.</description>
        <time_frame>9-12 week visit to 4-month visit</time_frame>
        <population>Subjects were excluded from this analysis if: they did not have ventricular pacing capture threshold measurements at 9-12 weeks or 4 months; or (for the MRI group) their MRI scan was not done according to protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>MRI Group</title>
            <description>The MRI group underwent a one-hour MRI scan at 9-12 weeks post-implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>The control group waited for one hour (no MRI scan) at 9-12 weeks post-implant</description>
          </group>
        </group_list>
        <measure>
          <title>Ventricular Pacing Capture Threshold Success</title>
          <description>Subjects' ventricular pacing capture threshold (the energy sent from the pacemaker needed to make the heart's ventricle beat) was measured at the 9-12 week visit (before the MRI scan was performed for those in the MRI group) and at the 4-month visit (one month post-MRI). Subjects were considered successful if their pacing capture threshold did not increase by 1.0 volt (V) or more.</description>
          <population>Subjects were excluded from this analysis if: they did not have ventricular pacing capture threshold measurements at 9-12 weeks or 4 months; or (for the MRI group) their MRI scan was not done according to protocol.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
                <count group_id="O2" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190"/>
                    <measurement group_id="O2" value="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: success rate MRI group &lt;= success rate control group - 10%</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin is 10%.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Farrington-Manning</method>
            <param_type>Difference in percentages</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Atrial Sensed Amplitude Success</title>
        <description>Subjects' atrial sensed amplitude (the minimum energy produced by the heart's atrium that the pacemaker can sense) was measured at the 9-12 week visit (before the MRI scan was performed for those in the MRI group) and at the 4-month visit (one month post-MRI). Subjects were considered successful if their sensed amplitude did not decrease by more than 50% and remained above 1.5 millivolts (mV).</description>
        <time_frame>9-12 week visit to 4-month visit</time_frame>
        <population>Subjects were excluded from this analysis if: they did not have atrial sensed amplitude measurements at 9-12 weeks or 4 months; or (for the MRI group) their MRI scan was not done according to protocol; or if their 9-12 week atrial sensed amplitude was less than 1.5 mV.</population>
        <group_list>
          <group group_id="O1">
            <title>MRI Group</title>
            <description>The MRI group underwent a one-hour MRI scan at 9-12 weeks post-implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>The control group waited for one hour (no MRI scan) at the 9-12 week follow-up.</description>
          </group>
        </group_list>
        <measure>
          <title>Atrial Sensed Amplitude Success</title>
          <description>Subjects' atrial sensed amplitude (the minimum energy produced by the heart's atrium that the pacemaker can sense) was measured at the 9-12 week visit (before the MRI scan was performed for those in the MRI group) and at the 4-month visit (one month post-MRI). Subjects were considered successful if their sensed amplitude did not decrease by more than 50% and remained above 1.5 millivolts (mV).</description>
          <population>Subjects were excluded from this analysis if: they did not have atrial sensed amplitude measurements at 9-12 weeks or 4 months; or (for the MRI group) their MRI scan was not done according to protocol; or if their 9-12 week atrial sensed amplitude was less than 1.5 mV.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: success rate MRI group &lt;= success rate control group - 10%</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin is 10%.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Farrington-Manning</method>
            <param_type>Difference in percentages</param_type>
            <param_value>1.9</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ventricular Sensed Amplitude Success</title>
        <description>Subjects' ventricular sensed amplitude (the minimum energy produced by the heart's ventricle that the pacemaker can sense) was measured at the 9-12 week visit (before the MRI scan was performed for those in the MRI group) and at the 4-month visit (one month post-MRI). Subjects were considered successful if their sensed amplitude did not decrease by more than 50% and remained above 5.0 millivolts (mV).</description>
        <time_frame>9-12 week visit to 4-month visit</time_frame>
        <population>Subjects were excluded from this analysis if: they did not have ventricular sensed amplitude measurements at 9-12 weeks or 4 months; or (for the MRI group) their MRI scan was not done according to protocol; or if their 9-12 week ventricular sensed amplitude was less than 5.0 mV.</population>
        <group_list>
          <group group_id="O1">
            <title>MRI Group</title>
            <description>The MRI group underwent a one-hour MRI scan at 9-12 weeks post-implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>The control group waited for one hour (no MRI) at the 9-12 week follow-up.</description>
          </group>
        </group_list>
        <measure>
          <title>Ventricular Sensed Amplitude Success</title>
          <description>Subjects' ventricular sensed amplitude (the minimum energy produced by the heart's ventricle that the pacemaker can sense) was measured at the 9-12 week visit (before the MRI scan was performed for those in the MRI group) and at the 4-month visit (one month post-MRI). Subjects were considered successful if their sensed amplitude did not decrease by more than 50% and remained above 5.0 millivolts (mV).</description>
          <population>Subjects were excluded from this analysis if: they did not have ventricular sensed amplitude measurements at 9-12 weeks or 4 months; or (for the MRI group) their MRI scan was not done according to protocol; or if their 9-12 week ventricular sensed amplitude was less than 5.0 mV.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130"/>
                    <measurement group_id="O2" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: success rate MRI group &lt;= success rate control group - 10%</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin is 10%.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Farrington-Manning</method>
            <param_type>Difference in percentages</param_type>
            <param_value>2.1</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With System-related Complications</title>
        <description>Subjects with a complication related to the implanted system, which consisted of the pacemaker, leads to the right chambers of the heart (atrium and ventricle), pacemaker software, and programmer. All adverse events in the time frame were recorded at the subject's center and assessed by a centralized Adverse Event Advisory Committee. The committee determined whether each adverse event was a complication (requiring invasive intervention), and whether the event was related to the system.</description>
        <time_frame>Implant to 4 Months</time_frame>
        <population>All implanted subjects with either a 4-month follow-up or a system-related complication within the first 4 months post-implant are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Implanted Subjects</title>
            <description>All subjects undergoing an implant attempt</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With System-related Complications</title>
          <description>Subjects with a complication related to the implanted system, which consisted of the pacemaker, leads to the right chambers of the heart (atrium and ventricle), pacemaker software, and programmer. All adverse events in the time frame were recorded at the subject's center and assessed by a centralized Adverse Event Advisory Committee. The committee determined whether each adverse event was a complication (requiring invasive intervention), and whether the event was related to the system.</description>
          <population>All implanted subjects with either a 4-month follow-up or a system-related complication within the first 4 months post-implant are included.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="447"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: Percentage of subjects with complication &gt; 20%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>exact test of binomial proportions</method>
            <param_type>Percentage</param_type>
            <param_value>8.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>10.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>System Related Adverse Device Effects Due to Labeling Instructions</title>
        <description>Number of participants with adverse device effects (ADEs) that resulted from insufficiencies or inadequacies in the instructions for use or deployment of the device, or from user error. ADE's were investigator-reported.</description>
        <time_frame>Implant through 18 months post-implant</time_frame>
        <population>Includes all subjects undergoing an MRI using the instructions in the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>MRI Group</title>
            <description>The MRI group underwent a one-hour MRI scan at 9-12 weeks post-implant.</description>
          </group>
        </group_list>
        <measure>
          <title>System Related Adverse Device Effects Due to Labeling Instructions</title>
          <description>Number of participants with adverse device effects (ADEs) that resulted from insufficiencies or inadequacies in the instructions for use or deployment of the device, or from user error. ADE's were investigator-reported.</description>
          <population>Includes all subjects undergoing an MRI using the instructions in the protocol.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Arrhythmias</title>
        <description>Number of participants with sustained ventricular arrhythmias or asystole episodes that occurred during the MRI scan that were considered attributable to the MRI scan</description>
        <time_frame>During the MRI scan</time_frame>
        <population>Arrhythmia was defined as heart rate &gt; 150 beats per minute for &gt; 30 seconds. Asystole was defined as standstill 6 seconds in electrical activity of the heart. Episodes were assessed via pulse oximetry monitoring during MRI scans.</population>
        <group_list>
          <group group_id="O1">
            <title>MRI Group</title>
            <description>The MRI group underwent a one-hour MRI scan at 9-12 weeks post-implant.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Arrhythmias</title>
          <description>Number of participants with sustained ventricular arrhythmias or asystole episodes that occurred during the MRI scan that were considered attributable to the MRI scan</description>
          <population>Arrhythmia was defined as heart rate &gt; 150 beats per minute for &gt; 30 seconds. Asystole was defined as standstill 6 seconds in electrical activity of the heart. Episodes were assessed via pulse oximetry monitoring during MRI scans.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Atrial Lead Impedance Change</title>
        <description>Subjects' atrial lead impedance (a measure of electrical resistance) was measured at the 9-12 week visit (before the MRI scan was performed for those in the MRI group) and at the 4-month visit (one month post-MRI). Both measurements were conducted by the pacemaker. The difference between the two is reported.</description>
        <time_frame>9-12 week visit and 4-month visit</time_frame>
        <population>Subjects with non-missing data are included</population>
        <group_list>
          <group group_id="O1">
            <title>MRI Group</title>
            <description>The MRI group underwent a one-hour MRI scan at 9-12 weeks post-implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>The control group waited for one hour (no MRI) at the 9-12 week follow-up.</description>
          </group>
        </group_list>
        <measure>
          <title>Atrial Lead Impedance Change</title>
          <description>Subjects' atrial lead impedance (a measure of electrical resistance) was measured at the 9-12 week visit (before the MRI scan was performed for those in the MRI group) and at the 4-month visit (one month post-MRI). Both measurements were conducted by the pacemaker. The difference between the two is reported.</description>
          <population>Subjects with non-missing data are included</population>
          <units>ohms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="61.8"/>
                    <measurement group_id="O2" value="7.3" spread="50.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ventricular Lead Impedance Change</title>
        <description>Subjects' ventricular lead impedance (a measure of electrical resistance) was measured at the 9-12 week visit (before the MRI scan was performed for those in the MRI group) and at the 4-month visit (one month post-MRI). Both measurements were conducted by the pacemaker. The difference between the two is reported.</description>
        <time_frame>9-12 week visit and 4-month visit</time_frame>
        <population>Subjects with non-missing data are included</population>
        <group_list>
          <group group_id="O1">
            <title>MRI Group</title>
            <description>The MRI group underwent a one-hour MRI scan at 9-12 weeks post-implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>The control group waited for one hour (no MRI scan) at 9-12 weeks post-implant</description>
          </group>
        </group_list>
        <measure>
          <title>Ventricular Lead Impedance Change</title>
          <description>Subjects' ventricular lead impedance (a measure of electrical resistance) was measured at the 9-12 week visit (before the MRI scan was performed for those in the MRI group) and at the 4-month visit (one month post-MRI). Both measurements were conducted by the pacemaker. The difference between the two is reported.</description>
          <population>Subjects with non-missing data are included</population>
          <units>ohms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.0" spread="48.5"/>
                    <measurement group_id="O2" value="-5.7" spread="51.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Atrial Lead Handling Rating</title>
        <description>Physicians' rated atrial lead handling during the implant on a scale of -3 to +3 where: -3 = well below expectations; -2 = moderately below expectations; -1 = slightly below expectations; 0 = met expectations; +1 = slightly above expectations; +2 = moderately above expectations; and +3 = well above expectations.</description>
        <time_frame>During implant</time_frame>
        <population>All surveys completed are included</population>
        <group_list>
          <group group_id="O1">
            <title>5086 MRI Lead</title>
            <description>The 5086 MRI lead was used by all subjects in this study</description>
          </group>
        </group_list>
        <measure>
          <title>Atrial Lead Handling Rating</title>
          <description>Physicians' rated atrial lead handling during the implant on a scale of -3 to +3 where: -3 = well below expectations; -2 = moderately below expectations; -1 = slightly below expectations; 0 = met expectations; +1 = slightly above expectations; +2 = moderately above expectations; and +3 = well above expectations.</description>
          <population>All surveys completed are included</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ventricular Lead Handling Rating</title>
        <description>Physicians' rated ventricular lead handling during the implant on a scale of -3 to +3 where: -3 = well below expectations; -2 = moderately below expectations; -1 = slightly below expectations; 0 = met expectations; +1 = slightly above expectations; +2 = moderately above expectations; and +3 = well above expectations.</description>
        <time_frame>During implant</time_frame>
        <population>All surveys completed are included</population>
        <group_list>
          <group group_id="O1">
            <title>5086 MRI Lead</title>
            <description>The 5086 MRI lead was used by all subjects in this study</description>
          </group>
        </group_list>
        <measure>
          <title>Ventricular Lead Handling Rating</title>
          <description>Physicians' rated ventricular lead handling during the implant on a scale of -3 to +3 where: -3 = well below expectations; -2 = moderately below expectations; -1 = slightly below expectations; 0 = met expectations; +1 = slightly above expectations; +2 = moderately above expectations; and +3 = well above expectations.</description>
          <population>All surveys completed are included</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" spread="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Atrial Pacing Capture Threshold</title>
        <description>Average atrial pacing capture threshold. Pacing capture threshold is the energy needed to pace the heart.</description>
        <time_frame>3 or 4 months post-implant</time_frame>
        <population>Includes all subjects with data.</population>
        <group_list>
          <group group_id="O1">
            <title>MRI Group</title>
            <description>The MRI group underwent a one-hour MRI scan at 9-12 weeks post-implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>The control group waited for one hour (no MRI scan) at the 9-12 week follow-up.</description>
          </group>
        </group_list>
        <measure>
          <title>Atrial Pacing Capture Threshold</title>
          <description>Average atrial pacing capture threshold. Pacing capture threshold is the energy needed to pace the heart.</description>
          <population>Includes all subjects with data.</population>
          <units>Volts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.78" spread="0.28"/>
                    <measurement group_id="O2" value="0.77" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ventricular Pacing Capture Threshold</title>
        <description>Average ventricular pacing capture threshold. Pacing capture threshold is the energy needed to pace the heart.</description>
        <time_frame>3 or 4 months post-implant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MRI Group</title>
            <description>The MRI group underwent a one-hour MRI scan at 9-12 weeks post-implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>The control group waited for one hour (no MRI) at the 9-12 week follow-up.</description>
          </group>
        </group_list>
        <measure>
          <title>Ventricular Pacing Capture Threshold</title>
          <description>Average ventricular pacing capture threshold. Pacing capture threshold is the energy needed to pace the heart.</description>
          <units>Volts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.82" spread="0.30"/>
                    <measurement group_id="O2" value="0.90" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Atrial Sensed Amplitude</title>
        <description>Average atrial sensed amplitude.</description>
        <time_frame>3 or 4 months post-implant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MRI Group</title>
            <description>The MRI group underwent a one-hour MRI scan at 9-12 weeks post-implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>The control group waited for one hour (no MRI scan) at the 9-12 week follow-up.</description>
          </group>
        </group_list>
        <measure>
          <title>Atrial Sensed Amplitude</title>
          <description>Average atrial sensed amplitude.</description>
          <units>millivolt (mV)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="1.3"/>
                    <measurement group_id="O2" value="3.1" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ventricular Sensed Amplitude</title>
        <description>Average ventricular sensed amplitude.</description>
        <time_frame>3 or 4 months post-implant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>5086 MRI Lead</title>
            <description>The MRI group underwent a one-hour MRI scan at 9-12 weeks post-implant.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>The control group waited for one hour (no MRI scan) at 9-12 weeks post-implant</description>
          </group>
        </group_list>
        <measure>
          <title>Ventricular Sensed Amplitude</title>
          <description>Average ventricular sensed amplitude.</description>
          <units>millivolt (mV)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" spread="5.0"/>
                    <measurement group_id="O2" value="10.2" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 31 months.</time_frame>
      <desc>Serious AE:
AE that led to death, or led to worse health that resulted in: life-threatening illness or injury; a permanent impairment of a body function; hosp.; medical or surgery to prevent permanent impairment to body structure or a body function.
2 more MRI and 1 more control participants here due to a later freeze of adverse event data.</desc>
      <group_list>
        <group group_id="E1">
          <title>MRI Group</title>
          <description>The MRI group underwent a one-hour MRI scan at 9-12 weeks post-implant.</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>The control group waited for one hour (no MRI scan) at 9-12 weeks post-implant</description>
        </group>
        <group group_id="E3">
          <title>Non-randomized</title>
          <description>Some subjects were enrolled, but either did not receive a system, or received only a partial system, and were not randomized. Their adverse events were collected until they exited the study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="117" subjects_at_risk="260"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="260"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="17" subjects_affected="13" subjects_at_risk="260"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="207"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="260"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="260"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Cardiac perforation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nodal rhythm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pacemaker generated arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Arteriosclerotic retinopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Mesenteric artery stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pancreatic cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="260"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Implant site haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Implant site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Cholecytitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="260"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="207"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Implant site infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abscess soft tissue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Bacterial pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Enterocoocal bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Lead dislodgement</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="260"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Elevated pacing threshold</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="260"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Failure to capture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Inappropriate device stimulation of tissue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Postoperative thoracic procedure complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Therapeutic agent toxicity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Chronic myelomonocytic leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Fibroadenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Gliobastoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Haemangioma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Multiple myeloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma stage unspecified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Brain stem infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Cholinergic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Micturition disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Renal tubular acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Cytocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Endometrial disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="260"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Plural effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pulmoary oedema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Knee arthoplasty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Cardiac pacemaker revision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Subclavian vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="260"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="27" subjects_affected="24" subjects_at_risk="260"/>
                <counts group_id="E2" events="24" subjects_affected="19" subjects_at_risk="207"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Comparisons with a historical control (5076 Lead) were performed for secondary objectives #11-#16, however the results database is currently only designed to allow for reporting of participants specifically enrolled as part of this protocol.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>EnRhythm MRI Clinical Research Specialist</name_or_title>
      <organization>Medtronic, Inc</organization>
      <phone>800-328-2518 ext 62813</phone>
      <email>medtronicCRMtrials@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

